Di Tomaso, Emmanuelle,Germa, Marie-Caroline,Massacesi, Cristian,Fritsch, Christine,Schnell, Christian Rene,Tavorath, Ranjana
申请号：
AU2017245292
公开号：
AU2017245292A1
申请日:
2017.10.09
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017245292A120171102.pdf#####H: dar 1nterwoven NRPortb1 DCC DAR 15812107_ 1.doex-9/10/2017 Abstract The present invention relates to an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor compound of formula (1) or a pharmaceutically acceptable salt thereof for use in methods of treating or preventing a proliferative disease in a patient in need thereof by orally administering a therapeutically effective amount of said compound for at least two five-consecutive day cycles, wherein said compound is not administered to the patient for a period of about two days to about three days between said five-consecutive day cycles. Fig. I A 40 -- 12. 5mg&g 35 -.0 25 nguqg 30*'25 20 M E _ 10.o C. 5 0 0 2 4 6 a 10 12 14 16 18 20 22 24 Time post treatment (hours) B. so 60 -*r- 40 Weqk so -6- 00 _ g 50 .! 40 06 30 E 20 S10 0 2 4 6 8 10 12 14 16 18 20 22 24 Time post treatment (hours)
